Nestlé to buy rest of stake in Aimmune Therapeutics
Aimmune's Palforzia peanut allergy treatment, which recently gained US approval for children, has sales potential of $1bn
31 August 2020 - 10:28
Zurich — Nestlé plans to pay $2bn to gain full ownership of peanut allergy treatment maker Aimmune Therapeutics, as the Swiss company expands its fast-growing health science business.
Known for its KitKat chocolate bars and Nescafe instant coffee, Nestlé set up Nestlé Health Science (NHS) in 2011 to open up a new area of business between food and pharma...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.